Abstract
Molecular targeted agents have enlarged the armamentarium of anti-cancer therapies. Along with the success of some anti-growth factor receptors, signal transduction inhibitors represent a promising anti-cancer strategy. The PI3K-AKT-mTOR pathway is a key pathway frequently altered in cancer cells. This manuscript provides an overview of the PI3K-AKT-mTOR pathway and its targeting in human malignancies. A focus is delivered for mTOR inhibitors.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Humans
-
Neoplasms / drug therapy
-
Neoplasms / physiopathology
-
Phosphatidylinositol 3-Kinases / physiology
-
Phosphoinositide-3 Kinase Inhibitors*
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use
-
Protein Kinases / physiology*
-
Proto-Oncogene Proteins c-akt / antagonists & inhibitors*
-
Proto-Oncogene Proteins c-akt / physiology
-
Signal Transduction
-
TOR Serine-Threonine Kinases
Substances
-
Antineoplastic Agents
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Kinase Inhibitors
-
Protein Kinases
-
MTOR protein, human
-
Proto-Oncogene Proteins c-akt
-
TOR Serine-Threonine Kinases